Answers are grounded in this paper and cite their sources.
Outcomes for glioblastoma (GBM) patients undergoing standard of care treatment remain poor. Here we discuss the portfolio of previously investigated immunotherapies for glioblastoma, including vaccine therapy and checkpoint inhibitors, as well as novel emerging therapeutic approaches. In addition, we explore the factors that potentially influence response to immunotherapy, which should be considered in future research aimed at improving immunotherapy efficacy.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: